Adipose tissue expresses all the renin-angiotensin system (RAS) components that play an important role in the adipogenesis, lipid and glucose metabolism regulation in an auto/paracrine manner. Th e classical RAS has been found to be over-activated during the adipose tissue enlargement, thus elevated generation of angiotensin II (Ang II) may contribute to the obesity pathogenesis. Th e contemporary view on the RAS has become more complex with the discovery of alternative pathways, including angiotensin-converting enzyme 2 (ACE2)/angiotensin (Ang)-(1-7)/Mas receptor, (pro)renin receptor, as well as angiotensin IV(Ang IV)/AT4 receptor. Ang-(1-7) via Mas receptor counteracts with most of the deleterious eff ects of the Ang II-mediated by AT1 receptor implying its benefi cial role in the glucose and lipid metabolism, oxidative stress, infl ammation, and insulin resistance. Pro(renin) receptor may play a role (at least partial) in the pathogenesis of the obesity by increasing the local production of Ang II in adipose tissue as well as triggering signal transduction independently of Ang II. In this review, modulation of alternative RAS pathways in adipose tissue during obesity is discussed and the involvement of Ang-(1-7), (pro)renin and AT4 receptors in the regulation of adipose tissue homeostasis and insulin resistance is summarized.
Over the past decade, substantial progress has been achieved regarding the adipose tissue metabolic function knowledge. Th e adipose tissue is now considered to be an active endocrine organ playing signifi cant role in the regulation of the body metabolism homeostasis.
Positive energy balance leads to the adipose tissue expansion that is associated with adipocytes hyperplasia and hypertrophia and signifi cantly affects the overall cell biology and tissue homeostasis (Kloting and Bluher 2014) . Adipose tissue enlargement is accompanied by severe dysfunctions of adipocyte with impaired glucose and fatty acid metabolism. Th e obesity-associated pro-infl ammatory state and oxidative stress, as response to severe hypoxia, increase the macrophage infi ltration into the adipose tissue inducing further infl ammation and expression of infl ammatory mediators including tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) and may cause dysregulation of the adipokines [adiponectin, leptin, resistin, angiotensin II (Ang II)] . Th e increased reactive oxygen species (ROS) secretion into peripheral blood from adipose tissue is involved in the induction of insulin resistance in skeletal muscle and adipose tissue and obesity-associated vascular diseases (Wang et al. 2007; Netzer et al. 2015) .
It has been shown that the rennin-angiotensin system (RAS) is complicated and not all the physiological and pathophysiological roles of the Ang II are completely understood. Many of the other angiotensin peptides have also physiological eff ects. In addition to the classical RAS components, several new peptides, with interesting biological activity, have recently been discovered. Th e important one is angiotensin (Ang)-(1-7) produced through the Ang II degradation by angiotensin-converting enzyme 2 (ACE2). It has a counter-regulatory role by opposing many actions of Ang II on AT 1 receptors (Donoghue et al. 2000; Tipnis et al. 2000) . Discovering the G-protein coupled Mas, as a functional receptor (MasR) for Ang-(1-7), has clearly established the ACE2/Ang-(1-7)/MasR axis as an active pathway of the RAS and opened new possibilities of RAS components interactions (Santos et al. 2003) . Moreover, the Mas-related G-protein-coupled receptor (MrgD), as a second receptor for Ang-(1-7), has been identifi ed (Tetzner et al. 2016) . To the contemporary view on the RAS has also contributed with novel receptors such as pro(renin) receptor (PRR) and angiotensin type 4 (AT 4 ) receptor identifi ed as a transmembrane insulin regulated aminopeptidase (IRAP) playing a potential role in the regulation of glucose homeostasis (Kalupahana and Moustaid-Moussa 2012) .
Th is review is aimed to bring recent knowledge about the role of the alternative pathways of RAS in the regulation of the adipose tissue metabolism during obesity development, focusing (i) on the ACE2/ Ang-(1-7)/MasR pathway; (ii) on the (pro)renin receptor as binding site for renin or pro(renin); (iii), and on IRAP/AT 4 receptor as binding site for Ang IV (Figure 1 ).
Local RAS in adipose tissue
Th e RAS belongs to one of the oldest hormone systems. Originally, it was only considered as a cardiovascular system. Th e classical pathway of RAS with the major biologically active hormone Ang II has been well clarifi ed (Figure 1) . Th e main physiological eff ects of Ang II mediated by AT 1 receptor lead to body fl uid volume increase and blood pressure (Lavoie and Sigmund 2003) . It has been found that the RAS is present in not only the circulating system, but also the peripheral tissue. RAS has been detected in diff erent organs with multiple and specifi c functions (Danser 1996) .
Th e expression of all the RAS components, including new alternative pathways, has been demonstrated in human and rodent adipose tissue (Jones et al. 1997; Karlsson et al. 1998; Engeli et al. 1999; Pinterova et al. 2000; Gembardt et al. 2005; Achard et al. 2007; Santos et al. 2010) . Adipocyte-produced angiotensinogen contributes to the circulating RAS, but the eff ect of the obesity on the angiotensinogen production is still inconsistent. Th e most of the studies have shown an increased adipocyte production of angiotensinogen during chronic energy excess in rodent obesity models and obese humans, whereas others have shown no change or reduction in its production (Kalupahana and Moustaid-Moussa 2012).
Classical versus alternative RAS pathways in pathogenesis of obesity
RAS and preadipocytes diff erentiation
Th e adipogenesis is a process of preadipocytes differentiation into the mature adipocytes (Cristancho and Lazar 2011). Adipogenesis has been extensively studied in vitro with the aim to determine the participation of adipocytes in the pathogenesis of insulin resistance to reveal the appropriate therapeutic and preventive strategies for metabolic disorders (Fonseca-Alaniz et al. 2007 ). During the preadipocyte diff erentiation, the transcription of key factors including CCAAT-enhancer-binding proteins (C/EBPs), peroxisome proliferator-activated receptor gamma (PPAR-γ), and adipocyte determination and diff erentiation-dependent factor 1/sterol regulatory element binding protein-1 (ADD1/SREBP-1), are activated (Armani et al. 2010 ) and the expression of adipocyte markers including fatty acid binding protein 4 (FABP4), insulin-regulated glucose transporter 4 (GLUT4), leptin and adiponectin increased (Rosen and MacDougald 2006; Left erova and Lazar 2009) . Th e studies on the models of the PPAR-γ expression suppression or stimulation have confi rmed that the PPAR-γ is the master regulator in the adipogenesis (Farmer 2006) .
Adipogenesis has been suggested to modulate the obesity and the onset of the obesity-related adverse metabolic consequences, such as metabolic syndrome. Experimental studies have revealed that RAS expressed in the adipose tissue is implicated in the regulation of the adipocyte formation and supported a role for Ang II as a negative regulator of adipogenesis (Schling and Loffl er 2001; Janke et al. 2002; Sharma et al. 2002; Matsushita et al. 2006; Mogi et al. 2006; Brucher et al. 2007; Th atcher et al. 2009 ). Inhibitory eff ect of Ang II on the adipocyte formation has been supported by observations that AT 1 receptor blockers may improve the preadipocyte diff erentiation (Fujimoto et al. 2004; Furuhashi et al. 2004; Zorad et al. 2006; Fuentes et al. 2010) . Reduced adipocyte formation by Ang II may lead to predominance of large dysfunctional adipocytes characterized by insulinresistant state and chronic infl ammation. AT 1 receptor blockers restore small-diff erentiated adipocytes and it seems that the mechanism of their action is dependent on PPAR-γ. Small diff erentiated adipocytes produce less TNF-α and more benefi cial adipokines such as adiponectin (Lenz and Fornoni 2008) .
AT 1 receptor and MasR are co-expressed in adipocytes and we could hypothesize considering the Ang II inhibitory eff ects on adipogenesis that ACE2/Ang-(1-7)/MasR axis may counterbalance anti-adipogenic eff ect of Ang II, thus may promote preadipocyte differentiation. So far, the reports dealing with the involvement of Ang-(1-7) in adipocyte formation are almost missing. Only few studies have demonstrated that ACE2 and MasR expression steadily increase the overtime during the 3T3-L1 diff erentiation and have a positive regulation of Ang-(1-7)/MasR signaling to accelerate adipogenesis, particularly, in the early stage (Gupte et al. 2008; Th an et al. 2013) . Moreover, the authors have revealed the adipogenic eff ect of Ang-(1-7) through activation of MasR as well as the counteracting interplays between Ang-(1-7)/MasR and Ang II/ AT 1 R signaling on the adipogenesis. Th e mechanism by which Ang-(1-7) promoted diff erentiation of human and 3T3-L1 preadipocytes included the activation of phosphatidylinositol-3-kinase (PI3K) and the inhibition of PPAR-γ phosphorylation since Ser-112 phosphorylation of this nuclear receptor inactivates its adipogenic activity (Th an et al. 2013) . However, more studies are needed to support the potential benefi cial eff ects of Ang-(1-7) on the preadipocyte diff erentiation.
RAS and metabolism of adipose tissue
ACE/Ang II/AT 1 R axis. Th e obesity is associated with over activation of both systemic and adipose RASs in humans and animals (Kalupahana and Moustaid-Moussa 2012). An interaction of Ang II with insulin signaling cascades in insulin-sensitive tissues including skeletal muscle and liver has been shown (Zhou et al. 2012) , supporting a direct role for Ang II in the development of insulin resistance (Kwon and Pessin 2013; Makki et al. 2013) . Although adipose tissue glucose uptake accounts for only a small part of the body, the mechanism of insulin action in this tissue is of a high importance, since the adipose RAS plays an important role in the pathogenesis of the obesity and insulin resistance (Olivares-Reyes et al. 2009 ). However, the molecular eff ect of Ang II on insulin signal transduction is controversial, since there is evidence that Ang II treatment may lead to enhanced insulin signaling through AT 1 R on adipocytes (Ogihara et al. 2002; Juan et al. 2005) . On the other hand, Ang II can inhibit the adipose tissue insulin-signaling cascade and impair the GLUT4 translocation and glucose transport into the cells, indirectly. Several studies have demonstrated that Ang II may mediate insulin resistance by oxidative stress increase via activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and the ROS production as well as by stimulating the infl ammatory pathways and dysregulating of the secretion of chemokines (Harrison et al. 2003; Skurk et al. 2004; Blendea et al. 2005; Lastra et al. 2009) . Th e angiotensinogen gene silencing decreased the expression of pro-infl ammatory markers, such as IL-6, TNF-α, and MCP-1 in adipocyte cell culture (Carroll et al. 2013 ). In the genetically obese mice or mice with diet-induced obesity (DIO), the AT 1 receptor blockade reduced the formation of the ROS in adipose tissue (Kurata et al. 2006) . Ang II inhibits the secretion of adiponectin and the secretion of this anti-infl ammatory hormone is increased aft er RAS blockers treatment (Furuhashi et al. 2004; Zorad et al. 2006) .
Another mechanism underlying the eff ect of Ang II on insulin sensitivity is that Ang II markedly inhibits adipogenic diff erentiation and the blockade of the RAS prevents adipocyte hypertrophy by promoting diff erentiation of preadipocytes and formation of new insulin sensitive adipocytes .
ACE2/Ang-(1-7)/MasR axis. Th e ACE2/Ang-(1-7)/ MasR axis is active in many organs, including cardiovascular system, kidneys, and adipose tissue and has been found to be implicated in vasorelaxation, antiproliferative, anti-infl ammatory, and anti-fi brotic effects (Montezano et al. 2015) .
Th e metabolic eff ects of Ang-(1-7) have been studied in various animal models and in vitro experiments, as summarized in Table 1 . Santos and colleagues (2008) have found out that genetic deletion of MasR in mice may have devasting eff ect on the lipid and glucose metabolism in adipose tissue, leading ultimately to a metabolic syndrome-like state (Santos et al. 2008) . Furthermore, the data obtained on MasR knockout mice have shown that the lack of Ang-(1-7) action through MasR may impair the response of adipocytes to the antilipolytic eff ect of insulin. Th e authors have suggested the involvement of a decrease in the adipose PPAR-γ expression, its target enzymes fatty acid synthase (FAS), and acetyl-CoA carboxylase (ACC) (Mario et al. 2012 ).
In rat model, that mimics human metabolic syndrome with insulin resistance state and dyslipidemia, generated by high-fructose diet, administration of Ang-(1-7) improved the insulin signaling in the adipose tissue through the activation of the insulin receptor/insulin receptor substrate-1/PI3K/protein kinase B (IR/IRS-1/PI3K/Akt) pathway via MasRdependent mechanism. Th is improvement was associated with a signifi cant decrease in IRS-1 serine phosphorylation and activation of other proteins, including Akt substrate of 160 kDa (AS160) and glycogen synthase kinase 3β (GSK-3β) (Giani et al. 2009; Munoz et al. 2012 ). Furthermore, long-term Ang-(1-7) treatment in rats fed with high-fructose or high-fat diets may lead to reduction of the total fat mass, adipocyte size, adipose infl ammation, and superoxide production by NADPH (Marcus et al. 2013; Santos et al. 2013) . In a novel transgenic rat model of inducible insulin resistance, the administration of a newly developed Ang-(1-7) nano-formulation exerts a positive eff ect on the insulin signaling by decreasing the serine phosphorylation of IRS-1 and increasing Akt phosphorylation in adipose tissue (Santos et al. 2014) . Recent study have shown that transgenic rats with increased plasma Ang-(1-7), caused by over expression of an Ang-(1-7)-releasing fusion protein, had a signifi cantly reduced adipose tissue mass associated with augmented action of Akt and increased expression of FABP4 and adiponectin in this tissue and decreased plasma triacylglycerides (Santos et al. 2010) . Moreover, chronic high circulating Ang-(1-7) level in this transgenic rats fed with high-fat diet protect against the adipose metabolic stress decreasing proinfl ammatory state .
In vitro studies have revealed that Ang-(1-7) may protect against an oxidative stress via MasR by decreasing ROS production and increasing adiponectin production in fully diff erentiated 3T3-L1 adipocytes. Additionally, Ang-(1-7) has been found to improve the glucose uptake into primary cultured mice adipocytes under both, the basal and insulin-stimulated states (Liu et al. 2012) . (Gupte et al. 2008) Abbreviation: Ang-(1-7) -angiotensin (1-7); MasR -Mas receptor; ACE -angiotensin converting enzyme; TAG -triacyglycerol; NADPH -nicotinamide adenine dinucleotide phosphate; Akt -protein kinase B; AS160 -Akt substrate of 160 kDa; GSK-3β -glycogen synthase kinase 3β; FABP4 -fatty acid-binding protein 4; COX2 -cyclooxygenase 2; IL-1β -interleukin 1β; HDL -high density lipoprotein; ROS -reactive oxygen species; PPARγ -peroxisome proliferator-activated receptor γ; FAS -fatty acid synthase; ACC -acetyl-CoA carboxylase; NEFA -non-esterifi ed fatty acids; GLUT4 -glucose transporter type 4; ADAM17 -disintegrin and metalloproteinase domain-containing protein 17. Explanatory notes:  -increase,  -decrease, X -without alteration.
Th e role of the endogenous ACE2 in maintaining the insulin sensitivity and metabolic profi le has been studied using ACE2 knockout mice (Takeda et al. 2013) or by the administration of ACE2 activator, diminazene aceturate (DIZE) (de Macedo et al. 2015) . Th e results have revealed that ACE2 protects against high-calorie diet-induced insulin resistance in mice (Takeda et al. 2013 ). Activation of ACE2 by oral DIZE treatment in mice improved the plasma lipid profi le, decreased the gene transcription of adipogenesis-related proteins (FAS, ACC), lowered the body weight, and reduced adipose tissue mass (de Macedo et al. 2015) . Gupte et al. (2008) have demonstrated that ACE2 expression in adipocytes is dysregulated in high-fat diet fed mice compared with the low-fat diet fed controls.
Taken together, these results may imply a benefi cial role of ACE2/Ang-(1-7)/MasR axis in the glucose and lipid metabolisms, oxidative stress, and insulin resistance as opposed to the ACE/AngII/AT 1 R axis, which is activated in obesity-associated metabolic diseases. Moreover, these results may indicate that in addition to ACE inhibitors and AT 1 R blockers, MasR agonists and ACE2 activators may represent new drugs for the treatment of metabolic syndrome.
Ang IV/AT 4 receptor axis. Angiotensin IV (Ang IV) has attracted a lot of attention, due to its unique role in the memory and learning enhancing and regulation of insulin signaling in the brain (Gard 2008; Wong et al. 2011) . IRAP (EC 3.4.11.3.) has been identifi ed as a placental leucin aminopeptidase/oxytocinase (Rogi et al. 1996) and also as the specifi c binding site for Ang IV in the brain AT 4 receptor (Albiston et al. 2001) . In insulin-responsive cells IRAP accompanies GLUT4 in specialized storage vesicles (GSV) cycling within intracellular compartments at the basal state (Keller et al. 1995; Ross et al. 1996) . However, IRAP has been found in a range of tissues independently of GLUT4 expression (Chai et al. 2004) .
IRAP is an essential regulator of the glucose uptake into the insulin-responsive cells. Adipose and muscle cells have a specialized mechanism to retain GSV intracellularly in the absence of insulin. IRAP possesses of three domains: extracellular catalytic, transmembrane, and N-terminal cytoplasmic that interacts with three proteins -tankyrase (Chi and Lodish 2000) , acyl-CoA dehydrogenase (ACD) (Katagiri et al. 2002) , and formins (Tojo et al. 2003) . Th e interaction of these proteins with IRAP appears to be involved in vesicular retention at the basal state and their traffi cking to the cell surface upon insulin stimulation (Keller et al. 1995; Chai et al. 2004; Keller 2004) . Th us, in response to insulin, GSV are translocated to plasma membrane where GLUT4 facilitates the glucose uptake into the cells and catalytic domain of IRAP gets from vesicle lumen to extracellular cell surface (Kandror et al. 1994; Bryant et al. 2002) . IRAP belongs to the M1 family of Zn-dependent metallopeptidases and it is considered as a major protein in the GSV (Jordens et al. 2010) . Catalytic domain of IRAP is responsible for the extracellular breakdown of peptide substrates such oxytocin, vasopressin, lysbradykinin, and somatostatin (Yamahara et al. 2000; Chai et al. 2004; Fernando et al. 2005; Wallis et al. 2007) .
IRAP, as a regulator of the glucose uptake, is suggested to play a role in the obesity pathogenesis. Insulin resistance is associated with an abnormal subcellular distribution and impaired translocation of GSV to plasma membrane. GLUT4 and IRAP are accumulated in high-density membrane fraction in basal state and insulin is not able to stimulate their traffi cking (Sinha et al. 1991; Garvey et al. 1998; Maianu et al. 2001; Keller 2004) . In vitro studies, using 3T3-L1 cells, have determined that cytosolic tail of IRAP is likely to be associated with AS160 at the basal state and dissociates in the response of insulin enabling the GSV to translocate to the cell surface (Larance et al. 2005; Peck et al. 2006) .
Th e role of IRAP in the regulation of metabolism has been confi rmed by the study of Niwa and co-workers (2015) who have found that the IRAPknockout mice may be protected from the development of high-fat diet-induced obesity. Glucose and insulin tolerance tests have revealed that the glucose disposal and the hypoglycemic eff ect of insulin are pronounced in IRAP-knockout mice aft er a high-fat diet (Niwa et al. 2015) .
We may only hypothesize from the previous data that besides the eff ect of IRAP on the modulation of the glucose uptake by increasing the GLUT4 traffi cking, another possible mechanism might be involved. It has been shown that endogenous IRAP substrate, oxytocin, regulates food intake, adipose tissue homeostasis and adipogenesis (Eckertova et al. 2011; Altirriba et al. 2015; Blevins and Baskin 2015) and decreased plasma oxytocin level has been found in obese mice, rats, and humans (Morton et al. 2012; Gajdosechova et al. 2014; Qian et al. 2014; Plante et al. 2015) . Moreover, oxytocin or oxytocin receptor defi cient mice develop obesity and impaired glucose tolerance (Takayanagi et al. 2008; Camerino 2009) . We have previously shown that obesity-associated reduction in plasma oxytocin levels is due to increased peripheral peptide degradation by adipose tissue and liver, rather than changes in hormone synthesis (Gajdosechova et al. 2014) . Th us, inhibition of oxytocinase activity of IRAP may prolong the benefi cial peptide action on the adipose tissue metabolism and insulin sensitivity. Th e inhibitors of IRAP activity or compounds that could attract IRAP and GSV traffi cking to the cell membrane in order to facilitate glucose transport may represent a therapeutic potential for the treatment of resistant obesity (Amri 2016) .
Th e concept of Ang IV as an inhibitor of IRAP and its positive central eff ects on the learning and memory have stimulated the development of new selective inhibitors of IRAP (Albiston et al. 2008; Albiston et al. 2011; Mountford et al. 2014) . However, the impact of IRAP/AT 4 R axis on the energy metabolism has been hardly even elucidated and there is need for further studies that will open a view into the IRAP complex physiological eff ects.
(Pro)renin/renin receptor (PPR) axis. Th e discovery of the PRR highlights the role of the cell surface in Ang II generation and opens new perspectives on the tissue RAS and prorenin or renin eff ects independent of Ang II (Nguyen et al. 2002) . PRR is a single transmembrane domain receptor containing 350 amino acids that interacts with V-ATPase (Nguyen and Contrepas 2008) . PRR specifi cally binds both the (pro)renin and renin. Th e binding of renin to PRR induces a 4-fold increase in the catalytic effi ciency of angiotensinogen conversion to Ang I, while the binding of (pro)renin leads to non-enzymatic activation of this renin precursor (Nguyen et al. 2002) . Moreover, binding of (pro)renin or renin to PRR triggers Ang II-independent intracellular signaling pathways associated with the activation of the mitogen-activated protein kinases (MAPK) and extracellular signal-regulated kinases 1 and 2 (ERK1/2) cascade, and the promyelocytic zinc fi nger transcription factor (PLZF). Activated PLZF suppresses PRR gene expression and stimulates p85α subunit of PI3K (Schefe et al. 2006; Nguyen and Contrepas 2008) . In mesangial cells, the activation of ERK1/2 pathway increased transcription of transforming growth factor β1 (TGF-β1) and expression of molecules involved in fi brosis and infl ammation (Huang et al. 2007) .
PRR is expressed in many tissues including brain, adipose tissue, endothelial cells, vascular smooth muscle cells, skeletal muscle, and kidney (Danser and Deinum 2005) . Th e expression of PRR in adipose tissue has been found in both subcutaneous and visceral fat depots in humans as well as rodents (Nagai et al. 2009; Achard et al. 2011; Tan et al. 2014 ) and the development of obesity has been found to be accompanied by PRR upregulation in adipose tissue (Achard et al. 2007; Achard et al. 2011; Tan et al. 2014) . Accordingly, in mice fed with high-fat/high-carbohydrate diet or in fructose-fed rats, inhibition of PRR using the handle region peptide (HRP), a PRR blocker, led to a reduction of visceral fat mass and adipocyte size with simultaneous improvement of the glucose tolerance, suggesting at least a partial role for PRR in the insulin resistance development (Nagai et al. 2009; Tan et al. 2014; Tan et al. 2016 ). Tan and co-workers (2014) have elucidated a potential mechanisms implicated in these observations as the stimulation of the adipogenesis, angiogenesis, and adiponectin production in subcutaneous adipose tissue accompanying by reduced expression of infl ammatory markers in visceral fat depots aft er HRP treatment leading to the activation of healthy fat storage in subcutaneous adipose tissue and normalization of the plasma free acid and triglyceride levels (Tan et al. 2014; Tan et al. 2016) .
In 3T3-L1 cells, knockdown of PRR by gene silencing signifi cantly decreased mRNA abundance of PPAR-γ and FABP4, indicating an important role for PRR in adipogenesis and fatty acid storage in adipocytes (Wu et al. 2016) . Th e specifi c deletion of PRR in adipocytes of male mice fed by a standard diet induced a marked reduction in all white adipose tissues without abnormal distribution of fat pads. Despite the lipodystrophy accompanied by hepatic steatosis, adipocyte-PRR-defi cient mice had normal glucose tolerance and decreased fasting glucose level. Interestingly, high-fat-fed mice with adipocyte-PRR defi ciency were resistant to diet-induced obesity and had improved glucose tolerance and fasting blood glucose when compared with wild type control (Wu et al. 2016) . Th ese data have pointed out the importance of the adipose tissue PRR role in the normal development of adipocytes, lipid, glucose, and insulin homeostasis.
Th ese new and preliminary fi ndings may indicate that renin and (pro)renin via PRR, by Ang II-dependent or -independent manner, may play an important role in the modulation of the adipose tissue homeostasis and functions, and that PRR may substantially contribute to the pathophysiology of obesity and insulin resistance.
Perspectives and conclusion
Th e research progress made over the past few decade has defi ned the role of the alternative RAS pathways in the regulation of the adipose tissue metabolism. In addition to cardiovascular system, the establishing the active and functional ACE2/Ang-(1-7)/MasR axis, as a counter regulatory pathway of deleterious eff ects of Ang II in adipose tissue, opens a new perspective for the metabolic disorder pharmacotherapy. Demonstration of the importance of adipocyte (pro)renin receptor in the normal development of adipose tissue and its potential implication in obesity and insulin homeostasis may consider the (pro)renin receptor for a possible novel therapeutic target. Nevertheless, further investigation is necessary to identify the mechanisms by which the (pro) renin receptor regulates the adipose tissue and overall body metabolism.
